

CONFERENCE PROGRAMME

Sunday 14th October 2012	
08:00 –20:00	Conference Registration – Grand Ballroom Foyer
10:00 –11:30	Opening and welcome remarks & Plenary Session 1 Grand Ballroom Salons 1 & 2 Lessons of History and Future Vision for Vaccination
10:00 –10:10	Opening remarks: Shan Lu, President of ISV and Co-Chair; Bruce G. Weniger, Co-Chair; Floris de Hon, Publisher, Vaccine
10:10 –10:50	[O1.1] How introduction of HB vaccine into the EPI changed immunization forever. I. Gust, <i>University of Melbourne, Australia</i>
10:50 –11:30	[O1.2] Vaccines for 21st Century Society R. Rappuoli, <i>Novartis, Italy</i>
11:30 –13:00	Lunch Shanghai City Bistro
13:00 –14:55	Plenary Session 2 Grand Ballroom Salons 1 & 2 Influenza Vaccines for Human and Animal Populations Session Moderators: Adolfo Garcia-Sastre and Hualan Chen
13:00 –13:25	[O2.1] Vaccination against influenza: a moving target A. D.M.E.Osterhaus, <i>ErasmusMC, The Netherlands</i>
13:25 –13:50	[O2.2] Scientific challenges and progress in developing vaccines against pandemic influenza K. Subbarao, <i>National Institutes of Health, USA</i>
13:50 –14:15	[O2.3] Development of duck-enteritis-virus-vectored vaccines to prevent influenza and other diseases in poultry H. Chen, <i>Chinese Academy of Agricultural Sciences, China</i>
14:15 –14:25	[O2.4] A universal influenza virus vaccine based on chimeric hemagglutinin constructs F. Krammer*, N. Pica, R. Hai, A. García-Sastre, P. Palese, <i>Mount Sinai School of Medicine, USA</i>
14:25 –14:35	[O2.5] Sequential H1N1 infections elicit cross-reactive antibodies against emerging pandemic H1N1 influenza viruses D.M. Carter ¹ , C.J. Crevar ¹ , C.E. Bloom ¹ , J.L. Cherry ² , D.J. Lipman ² , T.M. Ross* ¹ , ¹ <i>University of Pittsburgh, USA</i> , ² <i>NIH, USA</i>
14:35 –14:45	[O2.6] Guillain-Barré Syndrome and pandemic influenza A(H1N1) 2009 vaccines: Meta-analysis of observational risk estimate studies from 2010 and 2011 D. Weibel* ¹ , C. Dodd ² , S. Romio ¹ , J. Bonhoeffer ^{3, 4} , S. Black ² , M. Sturkenboom ¹ , ¹ <i>Erasmus University Medical Center, The Netherlands</i> , ² <i>Cincinnati Children's Hospital Medical Center, USA</i> , ³ <i>Brighton Collaboration Foundation, Switzerland</i> , ⁴ <i>University Children's Hospital, Switzerland</i>
14:45 –14:55	[O2.7] The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine in the elderly in British Columbia. P.G. Van Buynder* ^{1, 2} , J.L. Van Buynder ¹ , M. Bigham ¹ , E. Brodtkin ¹ , S. Konrad ¹ , G. Ramler ¹ , ¹ <i>Fraser Health Authority, Canada</i> , ² <i>Simon Fraser University, Canada</i>
14:55 –15:25	Refreshment Break Grand Ballroom Foyer
15:25 –17:20	Plenary Session 3 Grand Ballroom Salons 1 & 2 Vaccines for Bacterial Diseases Session Moderators: Tom Evans and Betty Dodet
15:25 –15:50	[O3.1] Progress towards a vaccine for Staphylococcus aureus R. Daum, <i>University of Chicago MRSA Research Center, USA</i>
15:50 –16:15	[O3.2] Group A Streptococcal Vaccines: from Concept to Reality K. Kotloff, <i>University of Maryland, USA</i>
16:15 –16:40	[O3.3] Ongoing development of vaccines for Neisseria meningitidis serogroup B, Staphylococcus aureus, and Clostridium difficile. M. Young, <i>Pfizer Vaccine Clinical Research, China</i>
16:40 –16:50	[O3.4] Live attenuated bordetella pertussis as a single dose nasal vaccine against whooping cough and other respiratory diseases N. Mielcarek*, A.S. Debrie, P. Feunou, H. Kammoun, D. Raze, C. Locht, <i>Institut Pasteur de Lille, France</i>

16:50 –17:00	[O3.5] Using a registered salmonella vaccine as a delivery vector for campylobacter antigens P.M. Smooker*, M. Saxena, B. John, P.J. Coloe, <i>RMIT University, Australia</i>
17:00 –17:10	[O3.6] Study of the antigenic cross-reactivity between Neisseria meningitidis and commensal neisseria species using (DDA-BF) as adjuvant. F. Rinaldi ¹ , E. Gaspar ^{1,3} , A. Rosetti ² , N. Lincopan ² , E. De Gaspari ^{*1} , ¹ <i>Adolfo Lutz Institute, Brazil</i> , ² <i>São Paulo University, Brazil</i> , ³ <i>Embrapa Southern Region Animal Husbandry, Brazil</i>
17:10 –17:20	[O3.7] Protection against Clostridium difficile toxins A and B by antibodies elicited with DNA vaccines expressing the receptor-binding domain of toxin A and the enzymatic domain of toxin B K. Jin ¹ , S. Wang ^{*1,3} , C. Zhang ¹ , Y. Xiao ² , S. Lu ^{1,3} , Z. Huang ¹ , ¹ <i>The First Affiliated Hospital of Nanjing Medical University, China</i> , ² <i>Jiangsu Taizhou Haiyuan Protein Biotech, Co., Ltd, China</i> , ³ <i>University of Massachusetts Medical School, USA</i>
17:30 –20:30	Welcome Reception & Poster/Exhibition Session 1 Grand Ballroom Salon 3 All posters will remain available for viewing throughout the Congress until 14:00 Tuesday.

Monday 15th October 2012

08:30 –17:00	Conference Registration Grand Ballroom Foyer		
08:30 –10:25	Plenary Session 4 - sponsored by Inviragen Grand Ballroom Salons 1 & 2 Viral Disease Vaccines: Development and Applications Session Moderators: Yumei Wen and Marc Girard		
08:30 –08:55	[O4.1] A conditionally replication-defective vaccine with restored epithelial tropism to prevent cytomegalovirus (CMV) infection T.M. Fu, <i>Merck Research Laboratories, USA</i>		
08:55 –09:20	[O4.2] Recombinant VLP based human vaccines manufactured using E. coli platform Q.J. Zhao ^{*1,2} , S.W. Li ^{1,2} , J. Zhang ^{1,2} , N.S Xia ^{1,2} , ¹ <i>National Institute of Diagnostics and Vaccine Development in Infectious Disease, China</i> , ² <i>Xiamen University, China</i>		
09:20 –09:45	[O4.3] The PER.C6 cell platform for world supply of an affordable inactivated polio vaccine H. Schuitemaker, <i>Crucell Holland, The Netherlands</i>		
09:45 –09:55	[O4.4] Identification and development of a synthetic human cytomegalovirus gH/gL immunogen as a potent inducer of neutralizing antibodies D.J. Shedlock*, K.T. Talbott, S.J. Wu, C.M. Wilson, K. Muthumani, J.D. Boyer, <i>University of Pennsylvania, USA</i>		
09:55 –10:05	[O4.5] Prophylactic and therapeutic efficacy of attenuated Listeria monocytogenes-based vector vaccine delivering HPV16 E7 antigen to mice Y.Y. Jia, Y.L. Yin, H. Fu, M.Z. Hu, Z.M. Pan, X. Jiao*, <i>Yangzhou University, China</i>		
10:05 –10:15	[O4.6] Live measles virus as a vector for Chikungunya and Dengue vaccine development A. Habel ^{*1} , M. Müllner ¹ , E. Tauber ¹ , ¹ <i>Themis Bioscience, Austria</i> , ² <i>Institut Pasteur, France</i>		
10:15 –10:25	[O4.7] A single nucleotide mutation in NS2A of Japanese encephalitis live vaccine virus (SA14-14-2) ablates NS1 ¹ formation and contributes to attenuation Q. Ye, X.F. Li*, H. Zhao, S.H. Li, K.Y. Song, Y.Q. Deng, <i>Beijing Institute of Microbiology and Epidemiology, China</i>		
10:25 –10:55	Refreshment Break Grand Ballroom Foyer		
10:55 –12:25	Breakout Session A Grand Ballroom Salon 1 Influenza, Other Viral Disease Targets Session Moderators: Ted M. Ross and Hiroshi Kiyono		Breakout Session B Grand Ballroom Salon 2 Manufacturing Processing and Issues, Adjuvants, Novel Antigen Constructs and Disease Targets Session Moderators: Margaret Liu and Gregory Glenn
10:55 –11:05	[A1] To be determined	10:55 –11:05	[B1] High throughput screening for freeze-dried virusvaccine formulation A. Middelberg*, Y.P. Chuan, J. Mohr, L. HL Lua, <i>The University of Queensland, Australia</i>

11:05 –11:15	[A2] Pandemic H1N1 influenza vaccine induces hetero-subtypic antibody responses against group 1 influenza A viruses E. Vicenzi ¹ , ¹ <i>Ospedale San Raffaele, Italy</i> , ² <i>Institute for Research in Biomedicine, Switzerland</i>	11:05 –11:15	[B2] Process development of an affordable conjugate vaccine against the one of the major causes of enteric fever <i>Salmonella paratyphi A</i> . S. Kothari*, Y. Yoon, S. An, <i>International Vaccine Institute, Republic of Korea</i>
11:15 –11:25	[A3] A new strategy for repeated application of adenovirus vectored vaccines: proof-of-concept in rhesus macaques C.J. Sun ¹ , L.Q. Feng ¹ , Q.F. Luo ² , L.Q. Zhang ³ , L. Chen* ¹ , ¹ <i>Chinese Academy of Sciences, China</i> , ² <i>Guangzhou Institute of Respiratory Disease, China</i> , ³ <i>Tsinghua University, China</i>	11:15 –11:25	[B3] Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines R.D. Hess* ¹ , F. Weber ^{2,3} , K. Watson ⁴ , S. Schmitt ⁴ , ¹ <i>PAREXEL Consulting, Germany</i> , ² <i>Philipps-University Marburg, Germany</i> , ³ <i>Albert-Ludwigs Universität, Germany</i> , ⁴ <i>PAREXEL Consulting, UK</i>
11:25 –11:35	[A4] International harmonization of pandemic vaccination trials - An ethical and legal comparative analysis between Europe and the United States B. Buechner, <i>Indiana University, USA</i>	11:25 –11:35	[B4] Reverse genetic engineering of neuraminidase (NA) gene can improve the growth and yield of influenza virus H5N1 vaccine strain W.Q. Pan* ¹ , Z.Y. Dong ^{1,2} , C.F. Li ¹ , L. Chen ^{1,2} , ¹ <i>Guangzhou College of Medicine, China</i> , ² <i>Chinese Academy of Sciences, China</i>
11:35 –11:45	[A5] Development of recombinant H5N1 influenza vaccine based on vaccinia virus vector F. Yasui* ¹ , Y. Sakoda ² , H. Kida ² , Y. Itoh ³ , K. Ogasawara ³ , M. Kohara ¹ , ¹ <i>Tokyo Metropolitan Institute of Medical Science, Japan</i> , ² <i>Hokkaido University, Japan</i> , ³ <i>Shiga University of Medical Science, Japan</i>	11:35 –11:45	[B5] CD40 adjuvanted lymphoma vaccine A.W. Heath*, J. Carlring, T. Sultana, M.J. Szabo, E. DeLeenheer, R. Dickinson, <i>University of Sheffield, UK</i>
11:45 –11:55	[A6] Live attenuated SIV vaccine induces profound polarisation of T memory responses and requires occult replication for maintenance M. Manoussaka ¹ , N. Berry ² , D. Ferguson ² , R. Stebbings ² , M. Robinson ² , M. Cranage* ¹ , ¹ <i>University of London, UK</i> , ² <i>National Institute of Biological Standards and Control, UK</i> , ³ <i>Academic Medical Center of the University of Amsterdam, The Netherlands</i>	11:45 –11:55	[B6] Adjuvant formulations designed to improve swine vaccine stability F. Bertrand*, J. Ben Arous, S. Deville, L. Dupuis, <i>SEPPIC, France</i>
11:55 –12:05	[A7] Construction and characterization of a novel HPV prophylactic vaccine candidate via surface presentation of L1 by <i>Shigella</i> lcsA D. Xu ¹ , D.P. Wang ¹ , M. Cao ¹ , X.F. Yang ¹ , J. Yu ^{1,2} , Y.L. Wang* ¹ , ¹ <i>Xi'an Jiaotong University, China</i> , ² <i>University of Strathclyde, UK</i>	11:55 – 12:10	[B9] Modular approach to construct a totally synthetic self-adjuvanting vaccine W. Zeng*, K. Horrocks, C.Y. Wong, <i>The University of Melbourne, Australia</i>

12:05 –12:15	[A8] Different immunological pathways of vaccination failure - an investigation with Hepatitis B and Tick borne encephalitis (TBE) non-responder U. Wiedermann*, E. Garner-Spitzer, A. Wagner, M. Paulke-Korinek, H. Kollaritsch, F. Heinz, <i>Medical University Vienna, Austria</i>		
12:15 –12:25	[A9] Challenges in the development of a novel dengue vaccine for worldwide use J.E. Osorio ^{1,2} , A.H. Haller ¹ , I.D. Velez ³ , C.D. Partidos ¹ , C.Y. Huang ⁴ , D.T. Stinchcomb* ¹ , ¹ Inviragen, Inc., Fort Collins, CO, USA, ² University of Wisconsin, USA, ³ Universidad de Antioquia, Colombia, ⁴ Fort Collins, CO, USA		
12:25 – 14:45	Lunch & Poster/Exhibition Session 2 Shanghai City Bistro/ Grand Ballroom Salon 3		
13:15 – 14:45	ISV Annual General Meeting Grand Ballroom Salon 1		
14:45 – 16:45	Plenary Session 5 Grand Ballroom Salons 1 & 2 Clinical, Safety, and Post-Marketing Research Session Moderators: Ray Spier and Robert Chen		
14:45 –15:10	[O5.1] Catching our breath: Progress in the development of RSV vaccines R. A. Karron, <i>Johns Hopkins Bloomberg School of Public Health, USA</i>		
15:10 –15:35	[O5.2] Innovative Methods and Infrastructures for Vaccine Safety: The Case of Narcolepsy Following Pandemic Influenza Vaccine M. Sturkenboom, <i>Erasmus MC, The Netherlands</i>		
15:35 –15:45	[O5.3] Induction of antigen-specific B memory cells in subjects challenged with wild-type S. flexneri 2a R. Wahid* ¹ , J.K. Simon ² , W.L. Picking ³ , K.L. Kotloff ¹ , M.M. Levine ¹ , M.B. Szein ¹ , ¹ University of Maryland School of Medicine, USA, ² NanoBio Corporation, USA, ³ Oklahoma State University, USA		
15:45 –15:55	[O5.4] To be determined		
15:55 –16:05	[O5.5] Pre-clinical and clinical development of a vaccine for the prevention of hand foot and mouth disease caused by enterovirus 71 C. Thomson ¹ , P. Tong ¹ , Y.A. Lee ¹ , E. Caine ³ , S.H. Hwa ¹ , J. Brewoo ² , J. Santangelo* ¹ , ¹ Inviragen, USA, ² Inviragen, Singapore, ³ University of Wisconsin, USA		
16:05 –16:15	[O5.6] Duration of immunity induced by yellow fever vaccine in children L.A.B. Camacho* ¹ , O.A. Martins Filho ¹ , A.C.C. Azevedo ¹ , A.M.Y. Yamamura ¹ , J.A.C. Lemos ² , M.S. Freire ¹ , ¹ FIOCRUZ, Brazil, ² Secretaria Estadual de Saúde de Minas Gerais, Brazil		
16:15 –16:25	[O5.7] Safety of inactivated monovalent pandemic (H1N1) 2009 vaccination during pregnancy: a population-based study in Taiwan W.T. Huang*, F.W. Tang, H.W. Yang, S.E. Yang, Y.C. Chih, J.H. Chuang, <i>Taiwan Centers for Disease Control, Taiwan</i>		

16:25 –16:35	[O5.8] Control of rabies in wildlife by oral immunization: the Ontario (Canada) experience. R.C. Rosatte ¹ , P. Bachmann ¹ , D. Donovan ¹ , J.B. Campbell* ² , ¹ Ontario Ministry of Natural Resources, Canada, ² University of Toronto, Canada		
16:35 –16:45	[O5.9] Study of the integrated immune response induced by an inactivated EV71 vaccine prepared using human diploid cells L.D. Liu*, Y. Zhang, J.J. Wang, H.L. Zhao, L. Jiang, Q.H. Li, <i>Institute of Medical Biology, CAMS, China</i>		
19:15	Departure for Congress Dinner		
19:30 –22:30	Congress Dinner at Xian Qiang Fang Restaurant		
Tuesday 16th October 2012			
07:25 –08:25	Elsevier 'Scientific Publishing' Workshop Grand Ballroom Salons 1 & 2		
08:30 –10:10	Plenary Session 6 Grand Ballroom Salons 1 & 2 Technologies for Novel Antigen Constructs and Manufacturing Session Moderators: James B. Campbell and Anthony Fooks		
08:30 –08:55	[O6.1] Rational design of novel vaccines and biomarkers for tuberculosis prevention S.H.E Kaufmann, <i>Max Planck Institute for Infection Biology, Germany</i>		
08:55 –09:20	[O6.2] Review of the preclinical immunogenicity and efficacy, and clinical immunogenicity of an SF9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine: Insights into the pathogenesis of RSV and implications for subunit vaccine development G.M. Glenn*, G. Smith, R. Raghunandan, H. Li, B. Zhou, <i>Novavax, USA</i>		
09:20 –09:30	[O6.3] Dendritic cell interactions with nk cells: Implications for new adjuvant formulations in human vaccines B. Morandi ¹ , L. Mortara ² , L. Moretta ³ , G. Ferlazzo* ¹ , ¹ University of Messina, Italy, ² University of Insubria, Italy, ³ Istituto G. Gaslini, Italy		
09:30 –09:40	[O6.4] Antigen-expressing immunostimulatory liposomes: A novel genetically-programmable vaccine platform A. Lanzi* ¹ , M. Amidi ¹ , C.M. Fehres ² , T.D. de Gruijl ² , Y. van Kooyk ² , E. Mastrobattista ¹ , ¹ Utrecht University, The Netherlands, ² VU University Medical Center, The Netherlands		
09:40 –09:50	[O6.5] Systematic annotation and analysis of "virmugens" - virulence factors whose mutants can be used as live attenuated vaccines R. Racz, M. Chung, Z. Xiang, Y. He*, <i>University of Michigan, USA</i>		
09:50 –10:00	[O6.6] Biodistribution and lymph node retention of polysaccharide-based antigen nanocarriers S. Vicente* ¹ , B. Goins ² , A. Sánchez ¹ , M.J. Alonso ¹ , W.T. Phillips ² , ¹ University of Santiago de Compostela, Spain, ² University of Texas Health Science Center at San Antonio, USA		
10:00 –10:10	[O6.7] High protection of pigs against <i>Trichinella spiralis</i> induced by a vaccine based on a combination of recombinant proteins I. Vallee* ¹ , V. Laine-Prade ¹ , N. Versille ^{1,2} , S. Deville ² , Y. Yang ^{1,3} , M.Y. Liu ³ , ¹ Anses, Maisons-Alfort, France, ² Seppic, France, ³ Institute of Zoonosis, Jilin University, France		
10:10 – 10:40	Refreshment Break Grand Ballroom Foyer		
10:40 – 11:40	Breakout Session C Grand Ballroom Salon 1 Exotic Target Pathogens, Polio Strains, Immune Responses in Mice and Men Session Moderators: Stefan Kaufmann; Luiz Antonio Bastos Camacho		Breakout Session D Grand Ballroom Salon 2 Immunization Issues, Economics, and Impact; Acellular Pentavalent for China, Chronic Diseases Session Moderators: Punnee Pitisuttithum and Ann Oberg
10:40 –10:50	[C1] Enhancing Chikungunya virus immunity by improved vaccination K. Muthumani ¹ , N.Y. Sardesai ² , J.J. Kim ² , D.B. Weiner* ¹ , ¹ University of Pennsylvania School of Medicine, USA, ² Inovio Pharmaceuticals, USA	10:40 –10:50	[D1] Nonmedical exemptions to immunization requirements 2005-2011: Association between exemption rates and state policies for granting exemptions S.B. Omer* ^{1,2} , J.L. Richards ¹ , M. Ward ¹ , R.A. Bednarczyk ^{1,2} , ¹ Emory University, USA, ² Center for Health Research, USA

10:50 –11:00	[C2] Induction and characterization of broad cytotoxic T cells by protective vaccination against Marburg and Ebola D.J. Shedlock* ¹ , J. Aviles ² , K.T. Talbott ¹ , G. Wong ² , S.J. Wu ¹ , D.O. Villarreal ¹ , ¹ University of Pennsylvania, USA, ² University of Manitoba, Canada	10:50 –11:00	[D2] Cost of illness for economic evaluation: a case of rotavirus diarrhea in Vietnam A. Riewpaiboon* ¹ , D.A. Dang ² , S. Shin ³ , T.P.M. Le ² , D.T. Vu ² , T.H.A. Nguyen ² , ¹ Mahidol University, Thailand, ² National Institute of Hygiene and Epidemiology, Viet Nam, ³ International Vaccine Institute, Republic of Korea
11:00 –11:10	[C3] Immunogenicity of diphtheria-tetanus-acellular pertussis-Sabin inactivated poliovirus vaccine in rhesus monkey M.B. Sun* ¹ , S.M. Zhang ² , Y. Ma ¹ , X. Heng ¹ , H.J. Yang ¹ , S.D. Jiang ¹ , ¹ Chinese Academy of Medical Sciences & Peking Union Medical College, China, ² National Institute for Food and Drug Control, China	11:00 –11:10	[D3] Impact of PCV13: A 5 year prospective active surveillance (Heracles study) J.J. Picazo* ¹ , J. Ruiz-Contreras ² , J. Casado-Flores ³ , S. Negreira ² , M.J. Garía de Miguel ⁴ , T. Hernandez-Sampelayo ⁵ , ¹ Hosp. Clinico san carlos, Spain, ² Hosp. 12 de Octubre, Spain, ³ Hosp. Hosp. Nino Jesus, Spain, ⁴ Hosp. La Paz, Spain, ⁵ Hosp. Gregorio Maranon, Spain, ⁶ Hosp. Ramon y Cajal, Spain, ⁷ Pfizer, Spain
11:10 –11:20	[C4] A novel protective strategy by co-immunization against respiratory syncytial virus infection B. Wang* ^{1,2} , X. Chen ¹ , ¹ Fudan University, China, ² China Agricultural University, China	11:10 –11:20	[D4] The particularities of development of pentavalent combination vaccine and its 16-year worldwide clinical experiences J.D. Shu, Sanofi Pasteur, China
11:20 –11:30	[C5] Effects of routine immunization against perinatal transmission of hepatitis B virus in Jiangsu, China Y.H. Zhou* ¹ , J. Chen ¹ , C. Xu ² , S. Zhang ¹ , J. Wen ² , Y. Hu ¹ , ¹ Nanjing University Medical School, China, ² Zhenjiang Fourth People's Hospital, China	11:20 –11:30	[D5] Induction of antigen specific CTLs following DNA vaccination in humans: Implications from two clinical trials for treating cancer and chronic infectious diseases N.Y. Sardesai* ¹ , D.B. Weiner ² , M. Morrow ¹ , J. Yan ¹ , J. Boyer ² , M. Bagarazzi ¹ , ¹ Inovio Pharmaceuticals, Inc., USA, ² University of Pennsylvania, USA
11:30 –11:40	[C6] Development of recombinant Newcastle disease viruses expressing the glycoprotein (G) of avian metapneumovirus as bivalent vaccines Q. Yu, J.P. Roth, H. Hu, C.N. Estevez, L. Zsak, USDA-ARS, USA		To be determined
11:40 –12:40	Lunch & Poster/Exhibition Session 3 Shanghai City Bistro/ Grand Ballroom Salon 3		
12:40 –14:25	Plenary Session 7 – Sponsored by Inovio Grand Ballroom Salons 1 & 2 Tweaking the Immune System for AIDS and Other Targets: Prime-Boosting and Adjuvantation  Hosted by Japanese Society for Vaccinology; Session Moderators: Ken J. Ishii and Hideki Hasegawa		
12:40 –13:05	[O7.1] Update on the development of the Sanofi Pasteur tetravalent dengue vaccine A. Bouckennooghe, Sanofi Pasteur, Singapore		
13:05 –13:30	[O7.2] HIV vaccine research development: Beyond rv144 P. Pitisuttithum, Mahidol University, Thailand		
13:30 –13:55	[O7.3] Making immune sense of nucleic acids in inflammation and vaccination K.J. Ishii ^{1,2} , ¹ National Institute of Biomedical Innovation (NIBIO), Japan, ² WPI Immunology Frontier Research Center (IFREC), Japan		

13:55 –14:05	[O7.4] Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated cross-reactive effective memory T-cell immunity against different clades in non-human Chinese Rhesus macaques Y.M. Wan, C. Qiu, J. Wang, Z.D. Hu, X.N. Ren, J.Q. Xu*, <i>Fudan University, China</i>
14:05 –14:15	[O7.5] Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles S.C. Lin ¹ , Y.F. Lin ¹ , P. Chong ¹ , S.C. Wu* ^{1,2} , ¹ <i>National Tsing Hua University, Taiwan</i> , ² <i>NHRI, NIIDV, Taiwan</i>
14:15 –14:25	[O7.6] CCR10 ligand adjuvants enhance functional antibody titers N.A. Hutnick* ¹ , D.J.F. Myles ¹ , A.S. Khan ² , J. Yan ² , G. Kobinger ³ , N.J. Sardesai ² , ¹ <i>University of Pennsylvania, USA</i> , ² <i>Inovio Pharmaceuticals, USA</i> , ³ <i>University of Manitoba, Canada</i> , ⁴ <i>Tulane University, USA</i> , ⁵ <i>Drexel University, USA</i>
14:25 –14:55	Refreshment Break Grand Ballroom Foyer
14:55 –16:45	Plenary Session 8 Grand Ballroom Salons 1 & 2 The Decade of Vaccines for Diseases of Global Importance Session Moderators: Jose Esparza and Ian Gust
14:55 –15:05	Edward Jenner Poster Prize ceremony
15:05 –15:30	[O8.1] Introduction to the decade of vaccines R. Rabinovich, <i>Bill & Melinda Gates Foundation, USA</i>
15:30 –15:55	[O8.2] TB vaccine trials: Present and future T. Evans, <i>University of California, USA</i>
15:55 –16:20	[O8.3] Approaches to improved malaria vaccines - RTS,S and beyond R. Ballou, <i>GSK Vaccines, Belgium</i>
16:20 –16:45	[O8.4] New discovery on protective antibody responses by DNA priming immunization S. Lu, <i>University of Massachusetts Medical School, USA</i>
16:45 16:55	Closing Summary & Invitation to the 7th Vaccine and ISV Congress in Barcelona, Spain Floris de Hon, Publisher, Vaccine; Shan Lu, President of ISV and Co-Chair; Bruce G. Weniger & Adolfo Garcia-Sastre, 2013 7th Congress Co-Chairs